- Q1 2024 Taysha Gene Therapies Inc Earnings Call TranscriptMay 14, 2024$2.57 (+7.08%)Earnings
- Q4 2023 Taysha Gene Therapies Inc Earnings Call TranscriptMar 19, 2024$2.25 (+5.63%)Earnings
- Q3 2023 Taysha Gene Therapies Inc Earnings Call TranscriptNov 14, 2023$1.33Earnings
- Q2 2023 Taysha Gene Therapies Inc Earnings Call TranscriptAug 14, 2023$2.13 (+188.23%)Earnings
- Taysha Gene Therapies Inc R&D Day TranscriptJun 28, 2023
- Q1 2023 Taysha Gene Therapies Inc Earnings Call TranscriptMay 11, 2023$0.709 (-5.47%)Earnings
- Q4 2022 Taysha Gene Therapies Inc Earnings Call TranscriptMar 28, 2023$0.652 (-6.19%)Earnings
- Taysha Gene Therapies Inc Corporate Update Call TranscriptJan 31, 2023
- Q3 2022 Taysha Gene Therapies Inc Earnings Call TranscriptNov 08, 2022$2.2 (+10.00%)Earnings
- Taysha Gene Therapies Inc to Discuss Astellas Pharma's Strategic InvestmentCall TranscriptOct 25, 2022
- Q2 2022 Taysha Gene Therapies Inc Earnings Call TranscriptAug 11, 2022$3.95 (-19.06%)Earnings
- Taysha Gene Therapies Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Taysha Gene Therapies Inc Earnings Call TranscriptMay 16, 2022$3.32 (-3.49%)Earnings
- Taysha Gene Therapies Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Taysha Gene Therapies Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) TranscriptApr 01, 2022
- Q4 2021 Taysha Gene Therapies Inc Earnings Call TranscriptMar 31, 2022$6.52 (+6.02%)Earnings
- Taysha Gene Therapies Inc To Discuss TSHA-120 GAN Program Update Call TranscriptJan 31, 2022
- Taysha Gene Therapies Inc To Discuss TSHA-101 In GM2 Gangliosidosis Program Update Call TranscriptJan 27, 2022
- Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Taysha Gene Therapies Inc Earnings Call TranscriptNov 10, 2021$15.74 (+5.14%)Earnings
- Taysha Gene Therapies Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 28, 2021
- Taysha Gene Therapies Inc Angelman Syndrome Investor Day TranscriptOct 26, 2021
- Taysha Gene Therapies Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- Taysha Gene Therapies Inc To Discuss CLN7 Program Acquisition Call TranscriptOct 05, 2021
- Taysha Gene Therapies Inc To Host Virtual Key Opinion Leader (KOL) Webinar On TSHA-102 For Treatment Of Rett Syndrome Call TranscriptSep 22, 2021
- Taysha Gene Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Taysha Gene Therapies Inc To Host CLN1 KOL Webinar TranscriptAug 30, 2021
- Q2 2021 Taysha Gene Therapies Inc Earnings Call TranscriptAug 16, 2021$15.82 (-8.98%)Earnings
- Taysha Gene Therapies Inc To Host Manufacturing Investor Day TranscriptJul 27, 2021
- Taysha Gene Therapies Inc R&D Day 2 TranscriptJun 29, 2021
- Taysha Gene Therapies Inc R&D Day 1 TranscriptJun 28, 2021
- Taysha Gene Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Taysha Gene Therapies Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Q1 2021 Taysha Gene Therapies Inc Earnings Call TranscriptMay 11, 2021$21 (+2.34%)Earnings
- Taysha Gene Therapies Inc GAN Program Acquisition Call TranscriptApr 12, 2021
- Full Year 2020 Taysha Gene Therapies Inc Earnings Call TranscriptMar 03, 2021$25.21Earnings
Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and thank you for joining us today. My name is [Fauci Kash], and I'm an analyst at JPMorgan Selfcare Group. Before we get started, I just wanted to note that there will be no Q&A for the session. And with that, I'll pass it over to our speakers, RA Session, President, CEO and Founder of Taysha Gene Therapies; and Suyash Prasad, Medical Officer and Head of R&D.
Thanks, [Fauci]. Good morning, everyone. Thank you, guys, for having us this morning. I'm happy to be presenting an initial overview of our story. I'll just start with some forward-looking statements here. And here's a summary of the company really why we're so excited about what lies ahead for 2022, just starting with a couple of near-term value inflection points. We'll be reporting long-term durability and long-term safety data on our high-dose cohorts and our other therapeutic doses, from our lead program, TSHA-120 giant axonal neuropathy later this month.
We'll also be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)